The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials

This publication has 51 references indexed in Scilit:

• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
  The Lancet, 2004
• Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
  Nature Reviews Drug Discovery, 2003
• Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
  The Lancet, 2003
• Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
  JAMA, 2002
• Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary InterventionA Randomized Controlled Trial
  JAMA, 2002
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
  JAMA, 1998
• The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts
  New England Journal of Medicine, 1997
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
  New England Journal of Medicine, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995